Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Soleno Therapeutics (SLNO) Receivables - Other (2018 - 2019)

Soleno Therapeutics (SLNO) has disclosed Receivables - Other for 2 consecutive years, with $9000.0 as the latest value for Q3 2019.

For Q3 2019, Receivables - Other changed N/A year-over-year to $9000.0; the TTM value through Sep 2019 reached $9000.0, changed N/A, while the annual FY2018 figure was $64000.0, N/A changed from the prior year.
Receivables - Other hit $9000.0 in Q3 2019 for Soleno Therapeutics, down from $18000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $72000.0 in Q1 2019 and bottomed at $9000.0 in Q3 2019.